Cancer Letters
Volume 243, Issue 2 , Pages 202-210 , 18 November 2006

Hybrid aza-steroid alkylators in the treatment of colon cancer

  • Dimitrios T.P. Trafalis

      Affiliations

    • 1st Department of Medical Oncology, ‘Metaxa’ Cancer Hospital, Piraeus, Greece
    • Laboratory of Medicinal Chemistry, Faculty of Pharmacy, University of Patras, Greece
    • Corresponding Author InformationPresent address: 1st Department of Medical Oncology, ‘Metaxa’ Cancer Hospital, 15 Larnakos, 17341 Agios Dimitrios, Athens, Greece. Tel.: +30 210 971 5465; fax: +30 210 971 3766.

Received 15 October 2005 ,Revised 4 November 2005 ,Accepted 27 November 2005.

References 

  1. Camoutsis C, Trafalis DTP. An overview on the antileukemic potential of d-homo-aza- and respective 17β-acetamido- steroidal alkylating esters. Invest. New Drugs. 2003;21:47–54
  2. Catsoulacos P, Catsoulacos D. Conjugated systems of homo-aza-steroidal esters in cancer chemotherapy. Anticancer Res. 1994;14:2525–2528
  3. Trafalis DTP, Camoutsis C, Dalezis P, Papageorgiou A, Kontos M, Karamanakos P, et al. Antitumour effect of A- and D-lactam androgen nitrogen mustards on non-small cell lung carcinoma. J. BUON. 2004;9:75–82
  4. Catsoulacos P, Politis D, Wampler GL. A new steroidal alkylating agent with improved activity in advanced murine leukemias. Cancer Chemother. Pharmacol. 1979;3:67–70
  5. Catsoulacos P, Camoutsis C, Wampler GL. Effect of a D5-homo-aza-steroidal ester in P388 and L1210 murine leukemias. Oncology. 1982;39:59–60
  6. Catsoulacos P. Activity of 3b-hydroxy-13a-amino-13,17-seco-5a-androstan-17-oic-13,17-lactam p-bis(2-chloroethyl)aminophenoxy acetate (NSC-294859) on experimental tumor and leukemia systems. Oncology. 1983;40:290–292
  7. Catsoulacos P, Wampler GL. Activity of 3b-hydroxy-13a-amino-13,17-seco-5a-androstan-17-oic-13,17-lactam(p-bis(2-chloroethyl)amino)-phenylacetate (NSC-290205) in murine solid tumors. Oncology. 1982;39:109–112
  8. Catsoulacos P. Further studies on the anti-neoplastic activity of 3b-hydroxy-13a-amino-13,17-seco-5a-androstan-17-oic-13,17-lactam(p-bis(2-chloroethyl)amino)-phenylacetate (NSC-290205). Cancer Lett. 1984;22:199–202
  9. Wall ME, Abernethy SG, Carroll JFI, Taylor DJ. The effects of some steroidal alkylating agents on experimental animal mammary tumor and leukemia systems. J. Med. Chem. 1969;12:810–818
  10. Wampler GL, Catsoulacos P. Antileukemic effect of homo-aza-steroidal-ester of p-[bis(2-chloroethyl)amino]acetic acid. Cancer Treat. Rep. 1977;61:37–41
  11. Catsoulacos P, Boutis L. Aza-steroids. Beckmann rearrangement of 3β-acetoxy-5α-androstan-17-one oxime acetate with boron fluoride. Alkylting agents. Chim. Ther. 1973;8:215–217
  12. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl Cancer Inst. 1990;82:1107–1112
  13. Goldin A, Venditti JM, Geran R. The effectiveness of the anthracycline analog 4′-epidoxorubicin in the treatment of experimental tumors: a review. Invest. New Drugs. 1985;3:3–21
  14. N.I.H., Principles of laboratory animal care, N.I.H. publication, 85 (1985) 23.
  15. Boring CC, Squires TS, Tang T, Montgomery S. Cancer statistics. CA Cancer J. Clin. 1994;44:7–26
  16. Gatta G, Ciccolallo L, Capocaccia R, Coleman MP, Hakulinen T, Møller H, et al. EUROCARE Working Group, Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. Eur. J. Cancer. 2003;39:2214–2222
  17. E.S.M.O. . Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer. Ann. Oncol. 2005;16(Suppl. 1):i16–i17
  18. Wilkes GM. Therapeutic options in the management of colon cancer: 2005 update. J. Clin. Oncol. Nurs. 2005;9:31–44
  19. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist. 2005;10:250–261
  20. Haller DG. Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers. Semin. Oncol. 2004;31(6 Suppl. 14):10–16
  21. Kabara JJ, Holzschu DL, Catsoulacos P. Structure function activity of azasterols and nitrogen containing steroids. Lipids. 1976;11:7555–7562
  22. Ma D, Wamg G, Wang S, Kozikowski AP, Lewin NE, Blumberg PM. Synthesis and protein kinase C binding activity of benzolactam-V-7. Bioorg. Med. Chem. Lett. 1999;9:1371–1374
  23. Endo Y, Yokohama A. Role of the hydrophobic moiety of tumor promoters. Synthesis and activity of 2-alkylated benzolactams. Bioorg. Med. Chem. Lett. 2000;10:63–66
  24. Endo Y, Shimazu M, Fukasawa H, Driedger PE, Kimura K, Tomioka N, et al. Synthesis, computer modeling and biological evaluation of novel protein kinase C agonists based on a 7-membered lactam moiety. Bioorg. Med. Chem. Lett. 1999;9:173–178
  25. Catsoulacos P, Politis D, Wampler GL. Antitumor activity of homo-aza-steroidal esters of [p-bis(2-chloroethyl)amino]phenyl acetic acid and [p-bis(2-chloroethyl)amino]phenyl butyric acid. Cancer Chemother. Pharmacol. 1983;10:129–132
  26. Catsoulacos P, Catsoulacos D. Antitumor activity of homo-aza-steroidal esters of p-N,N-bis(2-chloroethyl)amino phenoxy acetic acid. Anticancer Res. 1993;13:1203–1208
  27. Catsoulacos P, Camoutsis C, Papageorgiou A, Adamiak-Margariti E. Cytostatic effect of homo-aza-steroidal esters in vivo and in vitro: structure-activity relationships. Anticancer Res. 1992;12:1617–1620
  28. Dalmases P, Gomez-Belinchon JI, Bonet J-J, Giner-Sorolla A, Schmid FA. Antineoplastic agents. II. A nitrogen mustard derivative of N-methylated steroidal lactam. Eur. J. Med. Chem. 1983;18:541–543
  29. Dalmases P, Cervantes G, Quintana J, Bonet J-J. Antineoplastic agents. V. Nitrogen mustards of systematically modified steroidal ring A lactams. Eur. J. Med. Chem. 1984;19:465–467
  30. Papageorgiou A, Ivanov IG, Markov GG, Koliais SI, Boutis L, Catsoulacos P. Interaction of homo-aza-steroidal ester of p-[bis-(2-chloroethyl)amino] acetic acid (ASE) with DNA of Ehrlich ascites tumor cells. FEBS Lett. 1983;153:194–198
  31. Shepherd RE, Huff K, McGuire WL. Brief communication: estrogen receptor interaction with antitumor agent estradiol mustard. J. Natl. Cancer Inst. 1974;53:895–897
  32. Catsoulacos P, Catsoulacos D. Conjugated systems of homo-aza-steroidal esters in cancer chemotherapy. Anticancer Res. 1994;14:2525–2528
  33. Catsoulacos P, Catsoulacos D. Hybrid anticancer compounds. Steroidal lactam esters of carboxylic derivative of N,N-bis(2-chloroethyl)aniline. Anticancer Res. 1991;11:1773–1778
  34. Aviram R, Deutsch A, Patya M, Nordenberg J, Mor C, Reiss R, et al. Biochemical tissue markers of human colorectal carcinoma. Dis. Colon Rectum. 1988;31:176–180
  35. Lorenzi M, Vindigni C, Minacci C, Tripodi SA, Iroatulam A, Petrioli R, et al. Histopathological and prognostic evaluation of immunohistochemical findings in colorectal cancer. Int. J. Biol. Markers. 1997;12:68–74
  36. Wagner HE, Toth CA, Steele GD, Thomas P. Metastatic potential of human colon cancer cell lines: relationship to cellular differentiation and carcinoembryonic antigen production. Clin. Exp. Metastasis. 1992;10:25–31
  37. Goldin A, Venditti JM. Progress report on the screening program at the Division of Cancer Treatment, National Cancer Institute. Cancer Treat. Rev. 1980;7:167–176
  38. Opolski A, Laskowska A, Madej J, Wietrzyk J, Klopocki A, Radzikowski C, et al. Metastatic potential of human CX-1 colon adenocarcinoma cells is dependent on the expression of sialosyl antigen. Clin. Exp. Metastasis. 1998;16:673–681
  39. Jessup JM, Petrick AT, Toth CA, Ford R, Meterissian S, O'Hara CJ, et al. Carcinoembryonic antigen: enhancement of liver colonization through retention of human colorectal carcinoma cells. Br. J. Cancer. 1993;67:464–470
  40. D.T.P. Trafalis, G.D. Geromichalos, C. Koukoulitsa, A. Papageorgiou, P. Karamanakos, C. Camoutsis, Lactandrate: A d-homo-aza-androsterone alkylator in the treatment of breast cancer, Breast Cancer Res. Treat. (in press) (published online: 01/12/2005).
  41. Pispirigos K, Catsoulakos P, Karakiulakis G. Evaluation of kidney and liver subacute toxicity of antitumor agents using serum biochemical parameters in rats. Biochem. Mol. Biol. Int. 1993;31:565–573
  42. Pispirigos K, Paradelis AG, Karakiulakis G. Evaluation of cardiac subacute toxicity of epirubicin, chlorambucil, cisplatin, methotrexate and a homo-aza-steroid ester with antitumor activity in rats using serum biochemical parameters. Arzneimittelforschung. 1997;47:92–96
  43. Kubota T, Kawamura E, Suzuki T, Yamada T, Toyoda H, Miyagawa T, et al. Antitumor activity and pharmacokinetics of estra-1,3,5 (10)-triene-3,17 beta-diol, 3-benzoate, 17-((4-(4-bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy) acetate) (Bestrabucil) in human tumor xenografts serially transplanted into nude mice. Jpn. J. Clin. Oncol. 1986;16:357–364
  44. Stathopoulos GP, Stergiou GS, Golematis B, Thalassinos N, Fillipakis M. Effect of adriamycin, 5-fluorouracil and mitomycin-C combination chemotherapy in advanced colorectal cancer. Oncology. 1995;52:306–309
  45. Colucci G, Maiello E, Gebbia V, Giuliani F, Serravezza G, Lelli G, et al. 5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group. Cancer. 1999;85:535–545
  46. Nanni O, Volpi A, Frassineti GL, De Paola F, Granato AM, Dubini A, et al. Role of biological markers in the clinical outcome of colon cancer. Br. J. Cancer. 2002;87:868–875
  47. Karr JP, Wajsman Z, Kirdani RY, Murphy GP, Sandberg AA. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients. J. Urol. 1980;124:232–236
  48. Levell MJ, Siddall JK, Rowe E, Glashan RW, Robinson MR, Pidcock NB. Relationship of testosterone, sex hormone binding globulin, and calculated free testosterone to subsequent clinical progress in patients with carcinoma of the prostate treated with bilateral orchidectomy or estrogens. Prostate. 1987;11:17–21
  49. Qiu Y, Langman MJ, Eggo MC. Targets of 17 beta-oestradiol-induced apoptosis in colon cancer cells: a mechanism for the protective effects of hormone replacement therapy?. J. Endocrinol. 2004;181:327–337
  50. Izbicki JR, Wambach G, Hamilton SR, Harnisch E, Hogenschurz R, Izbicki W, et al. Androgen receptors in experimentally induced colon carcinogenesis. J. Cancer Res. Clin. Oncol. 1986;112:39–46
  51. Catalano MG, Pfeffer U, Raineri M, Ferro P, Curto A, Capuzzi P, et al. Altered expression of androgen-receptor isoforms in human colon-cancer tissues. Int. J. Cancer. 2000;86:325–330

PII: S0304-3835(05)01043-8

doi: 10.1016/j.canlet.2005.11.034

Cancer Letters
Volume 243, Issue 2 , Pages 202-210 , 18 November 2006

Article Tools

* Image Usage & Resolution